Powered by lexis nexis

Bristol-Myers Squibb to Present Data That Advances Understanding of Effects of Immuno-Oncology Therapies on Cancer Biology and Patient Outcomes at AACR 2017

Mar 01, 2017 - Business Wire

Bristol-Myers Squibb Company (NYSE: BMY) today announced that new clinical data will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2017 in Washington, D.C., from April 1-5. Research to be presented represents the company's ongoing commitment to investigating long-term survival and safety data in advanced cancers, and to exploring the interaction between biomarkers and Immuno-Oncology (I-O) therapy across multiple tumor types. Results will be disclosed for Opd...